Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™

DEVON, Pa. – Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Patent Office has issued Patent No. 3687513, titled “Treatment of Fragile X Syndrome and Autism with Cannabidiol,” which includes claims directed to methods of treating one or more behavioral symptoms of Fragile X syndrome and methods of treating one or more behavioral symptoms of autism spectrum disorder by transdermally administering a therapeutically effective amount of cannabidiol (CBD).

This new patent, which expires in 2038, is part of an expanding international intellectual property portfolio covering the Company’s transdermal cannabidiol product candidate, Zygel™ CBD gel. There are currently five corresponding U.S. patents related to methods of treating Fragile X syndrome or autism spectrum disorder.

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.

Investor Contact

Peter Vozzo
ICR Westwicke
Office: 443.213.0505
Cell: 443.377.4767
[email protected]